comparemela.com

Latest Breaking News On - Shri raghunathan - Page 1 : comparemela.com

Noctrix Health Raises $40M to Commercialize Wearable for RLS

Noctrix Health closed a $40 million financing round to advance its wearable system for restless legs syndrome.

Evan caplanShri raghunathanDrug administrationNoctrix healthNoctrix health incAsahi kasei corporationNidra tonic motor activationSectoral asset managementAngelini venturesBreakthrough device designation

Noctrix Health Raises $40M in Series C Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Shri raghunathanNoctrix healthNoctrix health incAsahi kasei corporationSectoral asset managementAngelini venturesTonic motor activationRestless legs syndrome

New RSL Therapy Offers Respite to Medication-Refractory Patients

The therapy was found to provide a “substantial reduction” in symptoms for adult patients with RLS refractory to medications.

United statesCross sylviaJohn winkelmanShri raghunathanDisorders clinical research program at massachusettsNoctrix healthNoctrix health incDrug administrationBreakthrough device designationClinical sleepSleep disorders clinical research programMassachusetts general hospital

MCRA Helps Noctrix Secure Authorization for RLS Therapy

MCRA LLC assisted Noctrix Health in obtaining FDA marketing authorization for the NTX100 Tonic Motor Activation System for patients with RLS.

Shri raghunathanJohn doucetOffice of neurologicalDrug administrationNoctrix healthMotor activationPhysical medicine devices

MCRA Assists Noctrix Health with FDA Marketing Authorization via the De Novo Pathway for the NTX100 Tonic Motor Activation System

/PRNewswire/ MCRA, LLC, a leading medical device focused regulatory advisory firm and clinical research organization (CRO) integrating U.S. and.

United statesNew yorkShri raghunathanAlyssa howardJohn doucetDigital healthDrug administrationViscogliosi brothersRegulatory affairsClinical research organizationCenters for diseaseNoctrix healthBusiness developmentInternational regulatory affairsOffice of neurologicalClinical trial operations

vimarsana © 2020. All Rights Reserved.